A Study to Evaluate Safety and Efficacy of PBK_M2101

PHASE3UnknownINTERVENTIONAL
Enrollment

246

Participants

Timeline

Start Date

June 30, 2023

Primary Completion Date

May 31, 2024

Study Completion Date

June 30, 2024

Conditions
Intestinal DiseaseColonic DiseasesGastrointestinal DiseaseDigestive System Disease
Interventions
DRUG

PBK_M2101 2-Day

Subjects who are randomized into group test 1 will receive bowel preparation from evening to next morning.

DRUG

PBK_M2101 1-Day

Subjects who are randomized into group test 2 will receive bowel preparation on the same-day.

DRUG

Oral Sulfate Tablet 2-Day

Subjects who are randomized into group active comparative will receive bowel preparation from evening to next morning.

Trial Locations (1)

Unknown

RECRUITING

Seoul Asan Medical Center, Seoul

Sponsors
All Listed Sponsors
lead

Pharmbio Korea Co., Ltd.

INDUSTRY

NCT05923918 - A Study to Evaluate Safety and Efficacy of PBK_M2101 | Biotech Hunter | Biotech Hunter